The year's most popular stories

Share this article:
The year's most popular stories
The year's most popular stories

There are lots of ways to write the kind of story that ends up on a list like this. You could take a deep dive sharing exclusive projections for industry marketing spend. You can seriously examine the aggressive pricing for oncology drugs in the US. Or you can pen a commentary about Angelina Jolie's views on holistic treatment.

MM&M's year-end list also captures approval and pipeline analysis (Eliquis, Sovaldi, Lemtrada), insights into what doctors need—as opposed to what pharma thinks they want—and a look at medical advertising's best DTC ads ever. Here are the 10 that sparked heaviest reader interest in 2013:

1. Angelina Jolie's flawed message

2. Healthcare Marketers Trend Report: The Big Shift

3. Will Kadcyla suffer the same fate as Zaltrap?

4. Year-end approval clears Eliquis for launch

5. Docs to pharma marketers: you're not getting it

6. Merck buys controlling stake in Physicians Interactive

7. Lemtrada's future in doubt after reviewers flag safety issues

8. MM&M's Best DTC Ads Ever

9. Is the current agency model a joke?

10. The Pipeline Report 2014: Class Seekers

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...